Hong Kong stock market anomaly | Remegen (09995) rose by more than 5% again. The company stated that all businesses are progressing normally, and the controlling shareholder intends to increase shareholding in the company.
According to the WiseNews app, Remegen (09995) has risen more than 5% again, although this week's cumulative decline has exceeded 23%. As of press time, it has risen 5.46% to HKD 16.62, with a turnover of HKD 49.4734 million. In terms of news, Remegen issued a notice of abnormal fluctuations in stock trading. According to market rumors, some of the company's products' external authorization progress did not meet expectations. After the company's self-inspection, all business operations are currently proceeding as usual, without involving hot market concepts. The company also responded that it has a certain amount of cash reserves; commercialization brings a certain scale of cash flow; has adequate bank credit; and potential international cooperation may also come.
Remegen (09995): The company's A-share stock trading has had abnormal fluctuations, but all of the company's business is currently progressing normally.
Remegen (09995) announced that the company's A shares will be traded on July 8, 9, and 10, 2024...
RemeGen Reports Unusual Share Price Drop
HK stocks saw unusual movement as the biomedical sector rallied, boosted by bullish policies for innovative drugs. There are still multiple catalysts for the sector in the second half of the year.
According to the Wise Money APP, biopharmaceutical stocks rebounded collectively. As of the press release, Remegen (09995) rose by 8.06%, to HKD 14.74; Kexing Biotech-B (06990) rose by 7.46%, to HKD 142.6; Genscript Biotech (01548) rose by 5.08% to HKD 9.52, and Junshi Bio (01877) rose by 4.17% to HKD 13. News-wise, on July 5th, the State Council's executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Entire Chain." Previously, the National Medical Insurance Bureau released the "First Launch Price of New Marketed Chemical Drugs".
Hong Kong stock market anomaly | Remegen (09995) rebounds more than 7%. The company states that all operations are proceeding normally. The controlling shareholder plans to increase shareholding by up to 20 million Chinese yuan.
Remegen (09995) rebounded more than 7% and as of press time, rose 7.04%, at HKD 14.6, with a turnover of HKD 18.1965 million.
Remegen (09995.HK) stocks are experiencing abnormal fluctuations in trading, but all business operations of the company are currently progressing normally.
On July 10th, Gelunhui announced that the closing price of Remegen's (09995.HK) stocks had deviated from the expected value by more than 30% for three consecutive trading days, from July 8th to July 10th, 2024. This is considered an abnormal fluctuation in stock trading according to the relevant provisions of the Shanghai Stock Exchange Trading Rules and the Science and Technology Innovation Board Stock Abnormal Trading Real-time Monitoring Measures. Market rumors suggest that the progress of some of the company's products authorized for external use did not meet expectations. However, according to the company's self-inspection, all of its businesses are proceeding normally, and do not involve any hot concepts in the market. After further verification, the company did not find any other issues.
The market cap of the two cities evaporated by over 10 billion yuan. What happened to Remegen (09955, 688331.SH)?
Both industry-level and company-level bullish news seems to have no effect on Remegen (09955, 688331.SH). From the industry perspective, the recently released "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Industry Chain" proposes to strengthen policy guarantees throughout the whole industry chain, coordinate and utilize policies such as price management, medical insurance payment, commercial insurance, pharmaceutical procurement and use, investment and financing, optimize the evaluation and approval process and medical institution assessment mechanism, and jointly promote the breakthrough and development of innovative drugs; mobilize resources for scientific and technological innovation in all aspects, strengthen basic research in new drug development, and consolidate the foundation of China's innovative drug development. So far, Beijing, Guangzhou, Zhuhai and other places have successively issued
Hong Kong Stock Market anomaly report | Remegen (09995) falls another 3% to reach a new low, A-shares drop another 10%, the company responded that its cash reserve is sufficient.
According to the Zhī tōng Finance app, Remegen (09995) AH stocks fell sharply yesterday, with A-shares falling more than 10% today after hitting a limit yesterday. As of press time, H shares fell 3.43%, reported at HKD 13.52, with a turnover of HKD 91.3829 million. In terms of news, Remegen held a conference call yesterday and disclosed the meeting minutes in the announcement, including the progress of RC18 international cooperation, cash flow situation and foreign patent expiration issues. In response to the market's most concerned cash flow issue, the company replied that there is a certain amount of cash reserves in the account; commercialization has brought a certain scale of cash flow; and there is sufficient
Midday A-share market report: the Shenzhen Component Index rose by 0.26%, with the consumer electronics and semiconductor sectors leading the gains.
As of midday closing, the Shanghai Composite Index fell 0.01% to 2922.27 points, the Shenzhen Component Index rose 0.26%, and the Chinext Price Index fell 0.13%.
Hong Kong Stock Market Movement | Remegen (09995) AH stocks all decline, the controlling shareholder plans to increase shareholding by no more than 20 million yuan, previously announced a targeted additional issuance of 2.55 billion yuan.
Remegen Biopharmaceuticals (09995) Ah stocks fell heavily in the morning session, with the company's stock price falling nearly 40% in the past month. As of press time, the A shares fell by 12.95% and the H shares fell by 11.05%, with a reported price of HKD 15.62 and a trading volume of HKD 34.2739 million.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Remegen plans to obtain a series of shareholding from actual controllers, involving 10 million to 20 million yuan.
Remegen (09995) announced that the company's actual controllers Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, and Wei Jianliang continue to be bullish on the company's operation situation and have confidence in the company's future prospects. They plan to increase their shareholding of the company's shares through Yantai Rongchang Holding Group Co., Ltd., a company controlled by them, in a manner permitted by the Shanghai Stock Exchange trading system (including but not limited to centralized bidding, continuous bidding, and bulk trading) from July 9, 2024 to within 6 months, and the amount of this shareholding increase is not less than RMB 10 million and not more than RMB 200.
Remegen (688331.SH): The enterprise under the control of the actual controller plans to increase shareholding of company stocks by 10-20 million yuan.
On July 8th, Gelunhui reported that the actual controllers of Remegen (688331.SH), including Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Yang Minhua, Wen Qingkai, and Wei Jianliang, continue to be bullish on the company's operation, and have confidence in the company's future development prospects. They plan to increase their shareholding in the company through Yantai Rongchang Control Group Co., Ltd., a company controlled by them, within six months starting from July 9, 2024, using the trading system allowed by the Shanghai Stock Exchange (including but not limited to centralized bidding, continuous bidding, and block trading). The amount of this shareholding increase will not be less than RMB 10 million.
Hong Kong stocks are fluctuating. Biomedical stocks have all fallen back due to the policy of innovative drug bullishness. Institutions say that negotiating difficulty has increased in the new environment.
Biomedical stocks fell across the board. As of press time, Remegen (09995) fell 20.18% to HKD 17.24, Tigermed (03347) fell 6.59% to HKD 26.95, Wuxi AppTec (02359) fell 3.95% to HKD 27.95, and Junshi Bio (01877) fell 2.25% to HKD 12.18.
Remegen (09995.HK) had 536,000 shares of shareholding reduced by E Fund.
According to the latest equity disclosure information from the Stock Exchange, on June 18, 2024, Remegen (09995.HK) experienced a shareholding reduction of 536,000 shares with an average price of HKD 26.5858 per share by E Fund Management Co., Ltd., involving approximately HKD 14.25 million. After the reduction, E Fund Management Co., Ltd.'s latest shareholding decreased to 9.1615 million shares, and the shareholding ratio decreased from 5.12% to 4.83%.
We Think Some Shareholders May Hesitate To Increase RemeGen Co., Ltd.'s (HKG:9995) CEO Compensation
Key Insights RemeGen's Annual General Meeting to take place on 28th of June CEO Jianmin Fang's total compensation includes salary of CN¥5.43m The overall pay is 385% above the industry average R
Remegen (09995.HK) received 423,000 shareholdings from Norges Bank.
According to the latest equity disclosure information from the Stock Exchange, on June 17, 2024, Remegen (09995.HK) received 423,000 additional shareholdings from Norges Bank on the exchange at an average price of HKD 27.872 per share, with a total value of approximately HKD 11.79 million. After the increase, the latest number of shares held by Norges Bank has increased from 4.83% to 5.05%.
Remegen (09995) has opened a special settlement account for its fundraising financial products.
Remegen (09995) announced that the second board of directors' eleventh meeting was held on March 27, 2024 according to the announcement.
HKEX unusual market activity | Remegen (09995) rose more than 4% during trading, with clinical research on injection Vedolizumab achieving major endpoints.
According to the Zhitong Finance and Economics APP, Remegen (09995) rose more than 4% during trading and at the time of publication, rose 3.45% to HKD 27, with a turnover of HKD 18.1935 million. On June 13th, Remegen announced that the Phase III clinical study of the single-domain anti-HER2 antibody (trade name: Aidi Xi) for the treatment of HER2-positive breast cancer patients with liver metastasis achieved positive results and reached the primary research endpoint. The company plans to submit a listing application to the Drug Evaluation Center (CDE) of the National Medical Products Administration in the near future. It is reported that in 2023, Remegen's sales of injection-type vidisiclib in the pharmaceutical industry reached 17.3.
RemeGen Phase Three Breast Cancer Clinical Trial Meets Primary Endpoint; Shares Rise 3%
RemeGen (HKG:9995) met the primary endpoint of its phase three trial investigating the use of its Disitamab Vedotin for Injection for the treatment of breast cancer patients with liver metastases, acc
No Data